Cargando…
The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review
Tuberculosis (TB) remains a global health emergency, with an estimated 2 billion people infected across the world, and 1.4 million people dying to this disease every year. Many aspects of the causative agent, Mycobacterium tuberculosis, make this disease difficult for healthcare and laboratory resea...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832907/ https://www.ncbi.nlm.nih.gov/pubmed/33477812 http://dx.doi.org/10.3390/antibiotics10010091 |
_version_ | 1783641939949649920 |
---|---|
author | Lee, Chiyun Bhakta, Sanjib |
author_facet | Lee, Chiyun Bhakta, Sanjib |
author_sort | Lee, Chiyun |
collection | PubMed |
description | Tuberculosis (TB) remains a global health emergency, with an estimated 2 billion people infected across the world, and 1.4 million people dying to this disease every year. Many aspects of the causative agent, Mycobacterium tuberculosis, make this disease difficult for healthcare and laboratory researchers to fight against, such as unique pathophysiology, latent infection and long and complex treatment regimens, thus causing patient non-compliance with the treatment. Development of new drugs is critical for tackling these problems. Repurposing drugs is a promising strategy for generating an effective drug treatment whilst circumventing many of the challenges of conventional drug development. In this regard, the incorporation of immunomodulatory drugs into the standard regimen to potentiate frontline drugs is found to be highly appealing. Drugs of diverse chemical classes and drug categories are increasingly being evidenced to possess antitubercular activity, both in vitro and in vivo. This article explores and discusses the molecular entities that have shown promise in being repurposed for use in anti-TB adjunctive therapy and aims to provide the most up-to-date picture of their progress. |
format | Online Article Text |
id | pubmed-7832907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78329072021-01-26 The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review Lee, Chiyun Bhakta, Sanjib Antibiotics (Basel) Review Tuberculosis (TB) remains a global health emergency, with an estimated 2 billion people infected across the world, and 1.4 million people dying to this disease every year. Many aspects of the causative agent, Mycobacterium tuberculosis, make this disease difficult for healthcare and laboratory researchers to fight against, such as unique pathophysiology, latent infection and long and complex treatment regimens, thus causing patient non-compliance with the treatment. Development of new drugs is critical for tackling these problems. Repurposing drugs is a promising strategy for generating an effective drug treatment whilst circumventing many of the challenges of conventional drug development. In this regard, the incorporation of immunomodulatory drugs into the standard regimen to potentiate frontline drugs is found to be highly appealing. Drugs of diverse chemical classes and drug categories are increasingly being evidenced to possess antitubercular activity, both in vitro and in vivo. This article explores and discusses the molecular entities that have shown promise in being repurposed for use in anti-TB adjunctive therapy and aims to provide the most up-to-date picture of their progress. MDPI 2021-01-19 /pmc/articles/PMC7832907/ /pubmed/33477812 http://dx.doi.org/10.3390/antibiotics10010091 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lee, Chiyun Bhakta, Sanjib The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
title | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
title_full | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
title_fullStr | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
title_full_unstemmed | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
title_short | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
title_sort | prospect of repurposing immunomodulatory drugs for adjunctive chemotherapy against tuberculosis: a critical review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832907/ https://www.ncbi.nlm.nih.gov/pubmed/33477812 http://dx.doi.org/10.3390/antibiotics10010091 |
work_keys_str_mv | AT leechiyun theprospectofrepurposingimmunomodulatorydrugsforadjunctivechemotherapyagainsttuberculosisacriticalreview AT bhaktasanjib theprospectofrepurposingimmunomodulatorydrugsforadjunctivechemotherapyagainsttuberculosisacriticalreview AT leechiyun prospectofrepurposingimmunomodulatorydrugsforadjunctivechemotherapyagainsttuberculosisacriticalreview AT bhaktasanjib prospectofrepurposingimmunomodulatorydrugsforadjunctivechemotherapyagainsttuberculosisacriticalreview |